Combination of non-viral connexin 43 gene therapy and docetaxel inhibits the growth of human prostate cancer in mice

International Journal of Oncology

Volumn 30, Issue 1, 2007, Pages 225-231

  Fukushima, Masayoshi ^a   Hattori, Yoshiyuki ^a   Yoshizawa, Takashi ^a   Maitani, Yoshie ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Combination therapy; Connexin 43; Cytotoxicity; Docetaxel; Gene therapy; Non viral vector; PC 3 cells; Prostate cancer

Indexed keywords

CONNEXIN 43; DOCETAXEL; GJA1 PROTEIN, HUMAN; TAXOID;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CYCLE; CELL DIVISION; DRUG EFFECT; GENE THERAPY; GENETICS; HUMAN; MALE; MOUSE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CONNEXIN 43; GENE THERAPY; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 35348841286     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.1.225     Document Type: Article

References (37)

1. Gao X, Porter AT, Grignon DJ, Pontes JE and Honn KV: Diagnostic and prognostic markers for human prostate cancer. Prostate 31: 264-281, 1997.
2. Oh WK and Kantoff PW: Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 160: 1220-1229, 1998.
3. Syed S: Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls. Cancer 98: 2088-2090, 2003.
4. Beer TM, El Geneidi M and Eilers KM: Docetaxel (taxotere) in the treatment of prostate cancer. Expert Rev Anticancer Ther 3: 261-268, 2003.
5. Hong WK: The current status of docetaxel in solid tumors. An M.D. Anderson Cancer Center Review. Oncology 16: 9-15, 2002.
6. Pienta KJ: Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 28: 3-7, 2001.
7. Li Y, Li X, Hussain M and Sarkar FH: Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia 6: 158-167, 2004.
8. Knuechel R, Siebert-Wellnhofer A, Traub O and Dermietzel R: Connexin expression and intercellular communication in two-and three-dimensional in vitro cultures of human bladder carcinoma. Am J Pathol 149: 1321-1332, 1996.
9. Bruzzone R, White TW and Paul DL: Connections with connexins: the molecular basis of direct intercellular signaling. Eur J Biochem 238: 1-27, 1996.
10. Tsai H, Werber J, Davia MO, et al: Reduced connexin 43 expression in high grade, human prostatic adenocarcinoma cells. Biochem Biophys Res Commun 227: 64-69, 1996.
11. Hossain MZ, Jagdale AB, Ao P, LeCiel C, Huang RP and Boynton AL: Impaired expression and posttranslational processing of connexin43 and downregulation of gap junctional communication in neoplastic human prostate cells. Prostate 38: 55-59, 1999.
12. Habermann H, Ray V, Habermann W and Prins GS: Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer. J Urol 167: 655-660, 2002.
13. Mehta PP, Lokeshwar BL, Schiller PC, Bendix MV, Ostenson RC, Howard GA and Roos BA: Gap-junctional communication in normal and neoplastic prostate epithelial cells and its regulation by cAMP. Mol Carcinog 15: 18-32, 1996.
14. Yamasaki H: Role of disrupted gap junctional intercellular communication in detection and characterization of carcinogens. Mutat Res 365: 91-105, 1996.
15. Chen SC, Pelletier DB, Ao P and Boynton AL: Connexin43 reverses the phenotype of transformed cells and alters their expression of cyclin/cyclin-dependent kinases. Cell Growth Differ 6: 681-690, 1995.
16. Huang RP, Fan Y, Hossain MZ, Peng A, Zeng ZL and Boynton AL: Reversion of the neoplastic phenotype of human glioblastoma cells by connexin 43 (cx43). Cancer Res 58: 5089-5096, 1998.
17. Hirschi KK, Xu CE, Tsukamoto T and Sager R: Gap junction genes Cx26 and Cx43 individually suppress the cancer phenotype of human mammary carcinoma cells and restore differentiation potential. Cell Growth Differ 7: 861-870, 1996.
18. Zhang ZQ, Zhang W, Wang NQ, Bani-Yaghoub M, Lin ZX and Naus CC: Suppression of tumorigenicity of human lung carcinoma cells after transfection with connexin43. Carcinogenesis 19: 1889-1894, 1998.
19. Mehta PP, Perez-Stable C, Nadji M, Mian M, Asotra K and Roos BA: Suppression of human prostate cancer cell growth by forced expression of connexin genes. Dev Genet 24: 91-110, 1999.
20. Huang RP, Hossain MZ, Huang R, Gano J, Fan Y and Boynton AL: Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells. Int J Cancer 92: 130-138, 2001. (Pubitemid 32187042)
21. Fernstrom MJ, Koffler LD, Abou-Rjaily G, Boucher PD, Shewach DS and Ruch RJ: Neoplastic reversal of human ovarian carcinoma cells transfected with connexin 43. Exp Mol Pathol 73: 54-60, 2002.
22. Hattori Y and Maitani Y: Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase. Cancer Gene Ther 12: 796-809, 2005.
23. Igarashi S, Hattori Y and Maitani Y: Biosurfactant MEL-A enhances cellular association and gene transfection by cationic liposome. J Control Release 112: 362-368, 2006.
24. Robe PA, Jolois O, N'Guyen M, Princen F, Malgrange B, Merville MP and Bours V: Modulation of the HSV-TK/ ganciclovir bystander effect by n-butyrate in glioblastoma: correlation with gap-junction intercellular communication. Int J Oncol 25: 187-192, 2004.
25. Hattori Y, Kubo H, Higashiyama K and Maitani Y: Folate-linked nanoparticles formed with DNA complexes in sodium chloride solution enhance transfection efficiency. J Biomed Nanotech 1: 176-184, 2005.
26. Tanaka M and Grossman HB: Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells. Oncol Rep 11: 537-541, 2004.
27. Fujimoto E, Sato H, Nagashima Y, et al: A Src family inhibitor (PP1) potentiates tumor-suppressive effect of connexin 32 gene in renal cancer cells. Life Sci 76: 2711-2720, 2005. (Pubitemid 40409503)
28. Hattori Y and Maitani Y: Two-step transcriptional amplification-lipid- based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer. Cancer Sci 97: 787-798, 2006.
29. Hayashi N, Asano K, Suzuki H, Yamamoto T, Tanigawa N, Egawa S and Manome Y: Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate 65: 10-19, 2005.
30. Kasamon KM and Dawson NA: Update on hormone-refractory prostate cancer. Curr Opin Urol 14: 185-193, 2004.
31. Mesnil M, Krutovskikh V, Piccoli C, Elfgang C, Traub O, Willecke K and Yamasaki H: Negative growth control of HeLa cells by connexin genes: connexin species specificity. Cancer Res 55: 629-639, 1995.
32. Govindarajan R, Zhao S, Song XH, Guo RJ, Wheelock M, Johnson KR and Mehta PP: Impaired trafficking of connexins in androgen-independent human prostate cancer cell lines and its mitigation by alpha-catenin. J Biol Chem 277: 50087-50097, 2002.
33. Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM and Hussain A: Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 12: 169-174, 2006.
34. Muramaki M, Miyake H, Hara I and Kamidono S: Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model. Int J Oncol 26: 623-628, 2005.
35. Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U and Gleave ME: A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 4: 1689-1698, 2005.
36. Hasegawa S, Hirashima N and Nakanishi M: Microtubule involvement in the intracellular dynamics for gene transfection mediated by cationic liposomes. Gene Ther 8: 1669-1673, 2001. (Pubitemid 33085589)
37. Nair RR, Rodgers JR and Schwarz LA: Enhancement of transgene expression by combining glucocorticoids and antimitotic agents during transient transfection using DNA-cationic liposomes. Mol Ther 5: 455-462, 2002.